Хронический лимфолейкоз

НОВАЯ СТАТЬЯ

A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia.

PurposeVenetoclax-based treatment for chronic lymphocytic leukemia (CLL) can be a logistically burdensome regimen due to extensive required monitoring of tumor lysis syndrome (TLS)...

DOI: 10.1177/10781552251323195
Bailen RJ, Aasum MI, Tamminga LM, Koehler AB, Behnken AL, Harden J, Hampel PJ, Wang Y, Muchtar E, Kenderian SS, Kay NE, Rabe KG, Ding W, Call TG, Parikh SA
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2025-04-03
НОВАЯ СТАТЬЯ

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

У данной статьи нет абстракта.

DOI: 10.1038/s41375-025-02555-0
Bussot L, Poulain S, Nudel Ortmans M, Davi F, Roos-Weil D, Lepretre S, Richard D, Pastoret C, Desmares A, Ferrant E, Huet S, Sujobert P, Delabesse E, Ysebaert L, Lazarian G, Michallet AS, Bidet A, Dilhuydy MS, Delfau-Larue MH, Dupuis J, Clavert A, Dr
Leukemia, 2025-04-03
НОВАЯ СТАТЬЯ

Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study.

The CSHA CFS is a feasible tool for identifying older adults with CLL at higher risk of treatment toxicity and discontinuation. Patients with a CFS >3 had a significantly higher likelihood of treatment interruption due to adverse effects. Therefore, CSHA CFS can aid in stratifying patients and optimizing therapeutic strategies. Further validation in multicenter studies is warranted to confirm these results and explore the potential for adjusting treatment dosages based on frailty assessments in the era of targeted therapies.

DOI: 10.1016/j.jgo.2025.102219
Martino EA, Vigna E, De Luca P, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Fragliasso V, Neri A, Morabito F, Corsonello A, Gentile M
Journal of geriatric oncology, 2025-04-03

Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL.

Zanubrutinib is a selective second-generation Bruton tyrosine kinase inhibitor approved in various B-cell malignancies globally...

DOI: 10.1007/s12185-025-03925-1
Izutsu K, Ishikawa T, Shimada K, Kubo K, Kondo T, Fujimoto K, Fujisaki T, Kurahashi S, Nagafuji K, Sakai R, Jo T, Nakazato T, Sunami K, Kasahara S, Cohen A, Takai M, Zhong J, Takeuchi M
International journal of hematology, 2025-04-03